Clinevo Technologies | Clinical Research & Healthcare Technology Solutions

  The pharmaceutical landscape is currently witnessing an unprecedented explosion in data volume. From clinical trials and electronic health records to social media and scientific literature, the sources of safety data are multiplying exponentially. For   Pharmacovigilance (PV)   teams, this presents a critical dual challenge: managing vast quantities of data while ensuring stringent regulatory compliance with global bodies such as the FDA, EMA, and MHRA. The scale of this challenge is staggering. Consider that a single adverse event can be reported through multiple channels—spontaneous reports, literature mentions, social media discussions, and clinical trial databases. Each source requires intake, assessment, coding, and signal evaluation. Traditional manual processes, which were designed for a fraction of today’s data volumes, are buckling under the pressure. Case backlogs grow, signal detection delays increase, and compliance risks mount. This is where modern technolo...

  Pharmacovigilance teams aren’t being asked whether they use AI anymore — they’re being asked to prove they can control it.   That shift is what defines 2026. Regulators have moved beyond curiosity about machine learning in drug safety. They expect pharmaceutical organizations to demonstrate how AI systems are governed, validated, monitored, and audited across the safety lifecycle. The joint release of guiding principles by the FDA and EMA in early 2026 made one thing explicit:  AI governance in pharmacovigilance  must be explainable, traceable, and inspection-ready — no different from any other GxP-regulated system. For safety teams already using  AI for safety signal detection  and triage , or  adverse event case processing automation with AI , the focus has changed. It’s no longer about efficiency gains alone; now, the aim is to ensure every model decision, automation rule, and LLM-generated narrative can withstand regulatory scrutiny. Consequently...

  A mid-sized pharmaceutical company detected a hepatotoxicity signal 11 weeks after the first case report arrived. By then, hundreds of additional patients had received prescriptions. Their quarterly review cycle, standard practice for  signal detection , meant the pattern sat unexamined while their safety database accumulated cases. This delay is not rare. Most organizations still run signal detection monthly or quarterly using manual processes and the Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) methods developed in the 1990s. Meanwhile,  automated systems powered by machine learning algorithms  detect the same signals in days by analyzing patterns across multiple variables simultaneously. Learn why manual methods delay detection, how automation accelerates it, what integration actually requires, and which implementation decisions determine success. Why Traditional Signal Detection Methods Fall Short For decades,  pharmacovigilance teams ...

When a pharmaceutical company markets a drug, the safety monitoring journey is just beginning. Every week,  pharmacovigilance(PV) teams  must screen thousands of scientific publications from databases like PubMed and EMBASE, searching for adverse drug reactions that could signal emerging safety concerns.  The problem is that even if the PV team misses finding one critical case report, it can put patients at risk. On the flip side, when the same case appears across multiple journals and gets counted twice, regulatory authorities might see false signals that trigger unnecessary investigations. At this point,  literature monitoring  is becoming both a regulatory mandate and a significant operational challenge. However, artificial intelligence is changing how drug safety teams handle this workload. In this article, we will look at the specific challenges PV teams face in literature monitoring, various approaches to solve these problems, and how AI-powered solutions ...

  The pharmaceutical industry is currently facing a data deluge. As adverse event reporting channels expand from traditional forms to social media, patient support programs, and digital health apps, the volume of safety data is exploding. For pharmacovigilance (PV) teams, the manual processing of high-volume, unstructured adverse event data leads to delays, errors, and significant compliance risks. While automation has been a buzzword in the industry for years, a critical question has emerged in boardrooms and safety departments alike: How is AI transforming pharmacovigilance beyond big data analytics? The answer lies in the shift from static, rule-based automation to dynamic Generative AI (GenAI). This article explores the nuanced differences between GenAI pharmacovigilance and traditional automation, illustrating why advanced tools like  Clinevo Case Intake  are essential for modern drug safety monitoring. READ MORE